President and CEO, Novavax
Stanley Erck was named president and chief executive officer of Novavax in April 2011. He became a Novavax director in June 2009 and served as its executive chairman of the board beginning in February 2010. From 2000 to 2008, Mr. Erck was president and chief executive officer of IOMAI Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Mr. Erck previously served as president and chief executive officer at Procept, a publicly traded immunology company, as vice president of corporate development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the board of directors of MaxCyte, Inc. He received an undergraduate degree from the University of Illinois and a master’s degree in business administration from the University of Chicago Booth School of Business.